« Back
ESMO 2025 Congress
Oct 17 - Oct 21, 2025
Data on Immatics’ PRAME cell therapy, anzu-cel (anzutresgene autoleucel, IMA203), will be presented at the ESMO 2025 Congress in Berlin.
+++
Title: 1600O - Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a Ph 1 trial
Date: Monday, October 20, 2025
Session Time: 16:30 – 18:15 CET
Lecture Time: 17:14 - 17:26
Room: Berlin Auditorium - Hub 27
Presenting Author: Sapna Patel, MD
Session: Presidential Symposium III
ePoster Presentation
Title: SUPRAME: A Phase 3 trial evaluating IMA203 T-cell receptor (TCR) T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma
Location